Lecanemab Shows Promise In Early Stage Of Alzheimer’s
Japanese drugmaker Eisai revealed on Wednesday that its experimental drug “Lecanemab” is helpful for people in the early stage of Alzheimer’s disease.
The company has done a clinical 3 trial, but is yet to be peer-reviewed in any medical journal. According to the company’s new releases, “Lecanemab treatment met the primary endpoint and reduced clinical decline on the global cognitive and functional scale, CDR-SB, compared with placebo at 18 months, by 27%.”
Patients were monitored about how they do in areas like memory, judgment, problem-solving, and personal care.
Related Read: How to improve brain health through diet
Eisai, the drugmaker company, further revealed they would discuss the full results of the research at the conference in late November. The company is seeking approval from the U.S. Food and Drug Administration.
Eisai and Biogen will promote the drug together. Last year, Biogen’s Aduhelm introduced the first Alzheimer’s drug in nearly two decades. However, it flopped due to its high price.
A statement from the Alzheimer’s Association called “the clinical trial results” – the most encouraging at a time when there is no potential treatment for the disease available.
Alzheimer’s is a progressive neurological disorder that can cause the brain to shrink. It has no known cure yet. The treatments available in the market can just manage the symptoms, and the cause of the disease is still unknown.
